Holen Sie sich die Stockscreener-App
8.06
5.06%
-0.43
Handel nachbörslich:
8.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.49
Offen:
$8.48
24-Stunden-Volumen:
1.06M
Relative Volume:
0.65
Marktkapitalisierung:
$793.50M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-191.78M
KGV:
-4.1408
EPS:
-1.9465
Netto-Cashflow:
$-172.86M
1W Leistung:
+2.94%
1M Leistung:
-19.32%
6M Leistung:
+24.77%
1J Leistung:
+17.84%
1-Tages-Spanne:
$8.00
$8.63
1-Wochen-Bereich:
$7.65
$8.63
52-Wochen-Spanne:
$3.79
$11.45
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
8.06 | 776.77M | 14.79M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Guggenheim | Buy |
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SLDB|Solid Biosciences Inc|Price:7.830|Chg%:-0.150 - TradingKey
Solid Biosciences Inc (SLDB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Solid Biosciences Inc (SLDB) Income Statement - TradingKey
Solid Biosciences Inc (SLDB) Cash Flow - TradingKey
Solid Biosciences Inc (SLDB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Solid Biosciences (SLDB) Proxy filing Summary - Quartr
SLDB stock trades around recent lows as Solid Biosciences updates gene therapy pipeline - Ad-hoc-news.de
Solid Biosciences Slips 3.65% as Biotech Headwinds Weigh on SLDBRTH Profile - dars.gov.et
Solid Biosciences (SLDB) Registration filing Summary - Quartr
Solid Biosciences (SLDB) AGM 2026 Summary - Quartr
Solid Biosciences (SLDB) Q4 2025 earnings summary - Quartr
Solid Biosciences (SLDB) Declines Over 6% as Selling Pressure BuildsSign of Strength - dars.gov.et
How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices - Sahm
Solid Biosciences Inc (SLDB) Institutional Confidence - TradingKey
Is Solid Biosciences (SLDB) Undervalued Following Its Russell Growth Index Additions? - simplywall.st
Form 4 Solid Biosciences LLC For: 7 July By Investing.com - Investing.com South Africa
Director at Solid Biosciences (SLDB) converts 3,440 RSUs into shares - Stock Titan
Solid Biosciences updates gene therapy pipeline as investors watch clinical strategy - Ad Hoc News
Solid Biosciences (SLDB) Gains 2.12% as Biotech Momentum BuildsBreakout Stock Alerts - dars.gov.et
Solid Biosciences (SLDB) Rallies Nearly 5% as Stock Nears Resistance LevelDynamic Hedging - DonanımHaber
Solid Biosciences (SLDB) Surges 6.27% as Biotech Sentiment ImprovesHigh Low Breadth - dars.gov.et
Solid Biosciences stock hits 52-week high at $10.44 By Investing.com - Investing.com Canada
Solid Biosciences: The Bull Case Is No Longer Just Duchenne - Seeking Alpha
Does Solid Biosciences' (SLDB) Russell Index Debut Hint at a Turning Point in Its Growth Story? - simplywall.st
Solid Biosciences stock hits 52-week high at $10.44 - Investing.com
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base? - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Solid Biosciences Inc. - GuruFocus
Solid Biosciences Inc. connects with patients and stakeholders at 2026 annual Duchenne event - Traders Union
Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2500 Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2000 Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 3000E Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Enterprise value to EBITDA forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Price to book forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Price to earnings forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
SLDB Forecast — Price Target — Prediction for 2027 - TradingView
Solid Biosciences Inc. Actuals & Estimates (NASDAQ:SLDB) - TradingView
Solid Biosciences Inc. joins BAA 10K to fund cancer research advancement - Traders Union
Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 13D/A SOLID BIOSCIENCES INC. For: 24 June By Investing.com - Investing.com Australia
RA Capital discloses large SLDB stake with 8.18M pre-funded warrants - Stock Titan
RA Capital (NASDAQ: SLDB) boosts Solid Biosciences holding to 11.9% ownership - Stock Titan
Solid Biosciences Inc. joins Parent Project Muscular Dystrophy event to connect Duchenne community - Traders Union
SLDB Q1 2026 Earnings: Wider Loss Per Share Disappoints as Pre-Revenue Biotech Continues R&D SpendingEstimate Dispersion - dars.gov.et
Solid Biosciences Inc.(NasdaqGS: SLDB) added to S&P Biotechnology Select Industry Index - marketscreener.com
Solid Biosciences Jumps As H.C. Wainwright Lifts Price Target - timothysykes.com
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):